Biotech Startups

Thetis is a clinical-stage pharmaceutical company developing TP-317, an oral Resolvin E1 drug that activates the BLT1 receptor to restore tissue and immune balance. It is being developed for inflammatory bowel disease, including ulcerative colitis, and solid tumors.

1 investor

Third Pole develops portable and miniaturized devices that generate inhaled nitric oxide on-demand for hospital and mobile treatment of severe cardiopulmonary diseases and lung infections. The company uses a patented technology inspired by natural lightning to produce nitric oxide safely and efficiently from air and electricity.

1 investor

ThirtyFiveBio is a drug discovery company developing GPR35 antagonists to treat gastrointestinal diseases, with a focus on ulcerative colitis by targeting epithelial dysfunction. Founded in 2021, it operates as part of the Molecule to Medicine ecosystem and is advancing preclinical candidates toward first-in-human trials.

1 investor

Thoracic Innovations is a medical device company that develops products using computer-aided design, rapid prototyping, and 3D printing, with a focus on the cardiothoracic and thoracic clinical area.

1 investor

Thrive Bioscience develops the Thrive IQ software platform and CellAssist imaging systems that capture and analyze time-series morphological data on live cells, colonies, and organoids in culture. Its products produce ML/AI-ready phenotypic data sets for biologists and data scientists working in cell biology and bioprocessing.

1 investor

Thrombolex develops endovascular catheters using pharmaco-mechanical technology to treat arterial and venous thromboembolic (A+VTE) conditions by dissolving blood clots. Its FDA-cleared products are based on the BASHIR Endovascular Catheter platform for medical practitioners treating vascular disease.

1 investor

Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1). It is running a clinical study (Wave II) for people with Long QT Syndrome Type 2.

1 investor

Thunder Biotech is a cancer immunotherapy company developing MOTO-CAR treatments, which genetically engineer a patient's own macrophages into chimeric antigen receptor cells that target biomarkers on tumor cells to attack solid tumors. It focuses on immunotherapy for cancer patients with solid tumors.

1 investor

Thyreos develops recombinant herpesvirus-based vaccines for both animal and human health applications, designed to generate immune responses without affecting the nervous system. The company's platform targets herpesviruses that cause latent nervous system infections.

1 investor

A clinical-stage biotech company developing tissue-protective therapeutics, specifically focused on the drug Tiprelestat to prevent inflammatory organ damage in patients undergoing major surgery.

1 investor

Tigatx develops engineered IgA antibodies designed to engage neutrophils as a cancer treatment approach. The company focuses on first-in-class immunotherapy for cancer patients.

1 investor

TileBio develops self-supervised AI foundation models for digital pathology, applied to cancer diagnosis, prognosis, biomarker discovery, and drug development. It serves clinicians, diagnostics, and pharmaceutical research by analysing pathology imaging and sequencing data.

1 investor

TILT Biotherapeutics develops an investigational adenoviral immunotherapy platform for treating solid tumor cancers, with late-stage development of TILT-123 for head and neck cancer treatment. The company operates as a holding structure with distinct spin-out entities focused on clinical development and preclinical research.

1 investor

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases by acquiring drug assets against validated targets. Its lead program, CM313, is a CD38-targeting monoclonal antibody being tested across conditions including immune thrombocytopenia, systemic lupus erythematosus, and multiple myeloma.

1 investor

Time BioVentures is a venture capital firm that invests in life sciences and healthcare startups developing new medical and biotech technologies. It is based in Southern California.

1 investor

Timegate provides real-time process analytics tools for biopharmaceutical manufacturing using patented Timegated Raman Technology, which enables rapid spectral analysis of bioprocesses without fluorescence interference. The company serves biopharmaceutical manufacturers seeking quality control and process monitoring solutions.

1 investor

A venture capital firm that invests in the commercialization of research, with a focus on innovations emerging from the University of Melbourne and its affiliated medical research institutions and hospitals in the Melbourne Biomedical Precinct.

1 investor

Tinker Bio (霆科生物) develops microfluidics-based laboratory instruments, including an organ-on-a-chip culture and fluid control system (MOI-200), an automated microfluidic droplet generation system (DPS-300PRO), and a high-throughput microsphere preparation system (MSF-100). Its products serve life science research, drug screening, and clinical translation applications.

1 investor

The Tiny Cargo Co. isolates milk-derived exosomes from cow's milk at industrial scale and loads them with therapeutic cargoes such as peptides, RNAs, and biologics for oral drug delivery. It serves pharmaceutical partners developing therapeutics and is advancing XOlacta, a milk-exosome drug loaded with the aCT11 peptide as a cardioprotectant and radioprotectant.

1 investor

TippingPoint Biosciences is a therapeutics company developing a drug discovery platform that targets unstructured regions in chromatin proteins to treat diseases caused by dysfunctional genome chromatin packaging, with a focus on cancer. Its approach aims to increase specificity, reduce toxicity, and limit drug resistance in oncology treatments.

1 investor

Tissue Dynamics operates a drug discovery platform that uses real-time sensors, robotic automation, and AI software to grow and monitor human organoids at scale, generating human-relevant data on drug safety, efficacy, and toxicity. It serves pharmaceutical and biotech partners with compound profiling, screening, and target identification to de-risk and accelerate drug development.

1 investor

Title21 provides software solutions for cellular therapy and biopharmaceutical manufacturing organizations, offering digital tools for patient coordination, manufacturing workflows, quality management, and regulatory compliance.

1 investor

Tivenix develops a machine-learning software platform that analyzes epigenetic signatures in blood plasma to provide non-invasive diagnosis and progression monitoring of Alzheimer's disease and other neurodegenerative diseases. The company targets clinical diagnostics and its platform integrates with data from other biomarkers.

1 investor

TiVentures is a seed-stage venture capital fund, owned by the Fondazione Centenario BancaStato, that invests in early-stage technology companies based in southern Switzerland (Ticino). It focuses on the life science, medical, high-tech, and IT sectors.

1 investor